You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm's platform, dubbed HNKlear, uses methylation-specific PCR to detect microRNA biomarkers in a patient's blood sample following frontline cancer treatment.
The supplement adds a collection vial to the BD Onclarity test and includes performance data for the BD Viper LT and the BD COR Systems.
Patients with discordant p16 and HPV markers fall into an intermediate risk group, research presented at the European cancer conference suggests.
The researchers found that changes in histone modification at HPV integration events were correlated with upregulation of nearby genes and endogenous retroviruses.
The expanded test can be used for genotype risk-based patient monitoring to prevent over-treatment, BD has said.
The molecular test developed in collaboration with Self-screen identifies HPV 16 and 18 and concurrently detects the other 13 common high-risk types of HPV infection.
Emergency testing related to the SARS-CoV-2 pandemic strongly increased, but routine testing declined due to fewer regular health checks.
The test, which is used to screen for cervical cancer, was previously approved by the agency for use with the Cobas 4800 system.
Profiling microbial communities in cervicovaginal samples from women carrying high-risk HPV strains, researchers found possible markers of pre-cancer progression.
The company began offering testing to clinicians in the first quarter of this year and expects volume to grow significantly over the next several months.
The head of Operation Warp Speed tells Bloomberg he expects the paused AstraZeneca and Johnson & Johnson vaccine trials to resume soon.
A new UK government says socioeconomic factors, not genetics, account for disparities in deaths due to COVID-19 between ethnic groups, the Financial Times reports.
NPR reports on an Alzheimer's disease drug trial that is continuing despite the pandemic.
In Nature this week: CRISPR-Cas3 system for making large deletions efficiently, more.